187 related articles for article (PubMed ID: 36543790)
1. Molecular mechanism of antibody neutralization of coxsackievirus A16.
Zhang C; Liu C; Shi J; Wang Y; Xu C; Ye X; Liu Q; Li X; Qiao W; Yin Y; Cong Y; Huang Z
Nat Commun; 2022 Dec; 13(1):7854. PubMed ID: 36543790
[TBL] [Abstract][Full Text] [Related]
2. Structures of Coxsackievirus A16 Capsids with Native Antigenicity: Implications for Particle Expansion, Receptor Binding, and Immunogenicity.
Ren J; Wang X; Zhu L; Hu Z; Gao Q; Yang P; Li X; Wang J; Shen X; Fry EE; Rao Z; Stuart DI
J Virol; 2015 Oct; 89(20):10500-11. PubMed ID: 26269176
[TBL] [Abstract][Full Text] [Related]
3. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
4. The functional motions and related key residues behind the uncoating of coxsackievirus A16.
He XL; Du LF; Zhang J; Liang Y; Wu YD; Su JG; Li QM
Proteins; 2021 Oct; 89(10):1365-1375. PubMed ID: 34085313
[TBL] [Abstract][Full Text] [Related]
5. Coxsackievirus A16 utilizes cell surface heparan sulfate glycosaminoglycans as its attachment receptor.
Zhang X; Shi J; Ye X; Ku Z; Zhang C; Liu Q; Huang Z
Emerg Microbes Infect; 2017 Jul; 6(7):e65. PubMed ID: 28745308
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
7. A 3.0-Angstrom Resolution Cryo-Electron Microscopy Structure and Antigenic Sites of Coxsackievirus A6-Like Particles.
Chen J; Zhang C; Zhou Y; Zhang X; Shen C; Ye X; Jiang W; Huang Z; Cong Y
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093091
[TBL] [Abstract][Full Text] [Related]
8. Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
He M; Xu L; Zheng Q; Zhu R; Yin Z; Zha Z; Lin Y; Yang L; Huang Y; Ye X; Li S; Hou W; Wu Y; Han J; Liu D; Li Z; Chen Z; Yu H; Que Y; Wang Y; Yan X; Zhang J; Gu Y; Zhou ZH; Cheng T; Li S; Xia N
Cell Host Microbe; 2020 Feb; 27(2):249-261.e5. PubMed ID: 32027857
[TBL] [Abstract][Full Text] [Related]
9. Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.
Fan C; Ye X; Ku Z; Kong L; Liu Q; Xu C; Cong Y; Huang Z
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148783
[TBL] [Abstract][Full Text] [Related]
10. Small molecules targeting coxsackievirus A16 capsid inactivate viral particles and prevent viral binding.
Lin CJ; Liu CH; Wang JY; Lin CC; Li YF; Richardson CD; Lin LT
Emerg Microbes Infect; 2018 Sep; 7(1):162. PubMed ID: 30254193
[TBL] [Abstract][Full Text] [Related]
11. Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo.
Yao X; Mao Q; Li Y; Hao C; Bian L; Chen P; Gao F; Wu X; Lu W; Gao Q; Li X; Liang Z
Hum Vaccin Immunother; 2018 May; 14(5):1275-1282. PubMed ID: 29337652
[TBL] [Abstract][Full Text] [Related]
12. Genetic and Cross Neutralization Analyses of Coxsackievirus A16 Circulating in Taiwan from 1998 to 2021 Suggest Dominant Genotype B1 can Serve as Vaccine Candidate.
Cheng D; Chiu YW; Huang SW; Lien YY; Chang CL; Tsai HP; Wang YF; Wang JR
Viruses; 2022 Oct; 14(10):. PubMed ID: 36298861
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils.
Sun YS; Xia Y; Xu F; Lu HJ; Mao ZA; Gao M; Pan TY; Yao PP; Wang Z; Zhu HP
Emerg Microbes Infect; 2022 Dec; 11(1):1994-2006. PubMed ID: 35787233
[TBL] [Abstract][Full Text] [Related]
14. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
Jiang L; Fan R; Sun S; Fan P; Su W; Zhou Y; Gao F; Xu F; Kong W; Jiang C
Vaccine; 2015 Nov; 33(48):6596-603. PubMed ID: 26529072
[TBL] [Abstract][Full Text] [Related]
15. Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry.
Ku Z; Ye X; Shi J; Wang X; Liu Q; Huang Z
J Virol; 2015 Dec; 89(23):12084-95. PubMed ID: 26401034
[TBL] [Abstract][Full Text] [Related]
16. Immunological evaluation and comparison of different EV71 vaccine candidates.
Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
[TBL] [Abstract][Full Text] [Related]
17. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge.
Liu Q; Yan K; Feng Y; Huang X; Ku Z; Cai Y; Liu F; Shi J; Huang Z
Vaccine; 2012 Oct; 30(47):6642-8. PubMed ID: 22959985
[TBL] [Abstract][Full Text] [Related]
18. Immunological and biochemical characterization of coxsackie virus A16 viral particles.
Chong P; Guo MS; Lin FH; Hsiao KN; Weng SY; Chou AH; Wang JR; Hsieh SY; Su IJ; Liu CC
PLoS One; 2012; 7(11):e49973. PubMed ID: 23226233
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.
Lin CW; Liu CC; Lu TC; Liu SJ; Chow YH; Chong P; Huang MH
Biomed Res Int; 2014; 2014():670506. PubMed ID: 25006583
[TBL] [Abstract][Full Text] [Related]
20. Involvement of cell surface glycosaminoglycans in chebulagic acid's and punicalagin's antiviral activities against Coxsackievirus A16 infection.
Liu CH; Kuo YT; Lin CJ; Lin LT
Phytomedicine; 2023 Nov; 120():155047. PubMed ID: 37690230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
